{"id":"NCT00440947","sponsor":"ViiV Healthcare","briefTitle":"Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection","officialTitle":"See Detailed Description","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2007-02-27","resultsPosted":"2011-08-17","lastUpdate":"2012-03-22"},"enrollment":515,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Infection, Human Immunodeficiency Virus I","HIV Infection"],"interventions":[{"type":"DRUG","name":"Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)","otherNames":[]},{"type":"DRUG","name":"Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)","otherNames":[]}],"arms":[{"label":"Simplification","type":"OTHER"},{"label":"Continuation","type":"OTHER"}],"summary":"This study was designed to test the efficacy, safety, tolerability and durability of the antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC) Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by randomization to either a simplification regimen of ATV or continuation of ATV +/r for an additional 48 weeks, each in combination with ABC/3TC in antiretroviral (ART)-naive, HIV-1 infected, HLA-B\\*5701 negative subjects.\n\nAll subjects who complete the 84-week study will be eligible to enter the treatment extension phase and continue for an additional 60 weeks. The purpose of this extension is to obtain longer term treatment data in subjects who have completed the 84-week study.","primaryOutcome":{"measure":"Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit","timeFrame":"Week 84","effectByArm":[{"arm":"ABC/3TC + ATV: Randomized Phase","deltaMin":86,"sd":null},{"arm":"ABC/3TC + ATV/r: Randomized Phase","deltaMin":81,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.140"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":24},"locations":{"siteCount":72,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["18670229","20542844","20613461","24586911","23134624","23039030"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":515},"commonTop":["Diarrhoea","Blood bilirubin increased","Sinusitis","Hyperbilirubinaemia","Bronchitis"]}}